🏛️ Verified NIH Record • Updated 2026-01-26
REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy (NCT01984138)
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Polly A. Niravath, MD
🩺 Plain-English Summary (8th-Grade Level)
This study is investigating whether breast cancer patients who experience vaginal dryness while on anti-estrogen treatment could benefit from either vaginal estrogen or from a vaginal moisturizer called Replens.
Who can join: Review the eligibility criteria below.
Location: Houston Methodist Cancer Center — Houston, Texas
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Houston Methodist Cancer Center — Houston, Texas
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Estrogen Receptor Positive Breast Cancer
- FDG PET/CT in Breast Cancer Bone Mets — Philadelphia, Pennsylvania
- A Study to See Whether Estrogen Can Slow the Growth of Some ER Positive Breast Cancers — Edmonton, Alberta
Explore by condition: All Estrogen Receptor Positive Breast Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.